New drug a possible breakthrough for diabetic foot ulcers?

Treatment with polydeoxyribonucleotide (PDRN), an adenosine A2A-receptor agonist, nearly doubled the rate of complete healing of difficult-to-treat Wagner 1 or 2 diabetic foot ulcers compared with placebo, achieved earlier ulcer closure, and resulted in an “impressive” reduction in ulcer area as early as 8 weeks after the start of therapy, a new study indicates. The results are published online ahead of print in the Journal of Clinical Endocrinology & Metabolism.

View the original here:
New drug a possible breakthrough for diabetic foot ulcers?

Previous post:

Next post: